This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
BDX or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada
by Zacks Equity Research
Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
2 Unique Dividend Aristocrats to Diversify the Portfolio
by Shaun Pruitt
Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
by Zacks Equity Research
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
by Zacks Equity Research
PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a concern.
PerkinElmer (PKI) Completes Divestment, New Business Name in Q2
by Zacks Equity Research
PerkinElmer (PKI) completes separation of its businesses into two entities ¿¿¿ the AES business, and the Life Sciences and Diagnostics business.
3 Stocks to Buy for Consistent Dividend Growth
by Ethan Feller
Some of these companies have been around for over 100 years and have seen all imaginable economic environments
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
by Zacks Equity Research
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
BDX or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage
by Zacks Equity Research
Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage are included in this Analyst Blog.
Veeva Systems (VEEV) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Veeva Systems' (VEEV) Q4 results reflect impressive performances by both segments.
Top Analyst Reports for Schlumberger, Becton Dickinson & Marathon Petroleum
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Schlumberger Limited (SLB), Becton, Dickinson and Company (BDX) and Marathon Petroleum Corporation (MPC).
National Vision (EYE) Q4 Revenues Miss Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.